



Lyon, December 20th, 2017



11-12 December 2017
Lyon, France
Congress Center



Informations and Registrations: WWW.I4ID.ORG

“I4ID 2017”, the first international congress dedicated to immunotherapies for infectious diseases to take place in France, was a real success. I4ID 2018 is already on its way!

The congress, which took place on Monday 11th & Tuesday 12th December 2017 at Lyon’s congress center, gathered more than 175 attendees, 80 organizations, academics, businesses and 33 internationally renowned speakers.

Co-organised by the Technological Research Institute BIOASTER and the MabDesign association, this event was the first of its kind in France.

The diverse program of I4ID gathered, over two days, industrials, academics, clinicians, service providers, technology developers and international decision makers to discuss and exchange on immunotherapy as a new therapeutic way to fight emerging or re-emerging infectious diseases. www.I4ID.org

Thanks for their support:



« The emergence of new infectious diseases, the re emergence of “old” infectious diseases, the rise of antibacterial resistance to conventional antibacterial agents and the difficulty to come out with a new pipeline of new antimicrobial compounds leads to consider the potential of non-conventional approaches, such as immunotherapies as new therapies. »

Patrick Lécine, PhD, Scientific expert, immunology & vaccinology, Vaccines program, BIOASTER.

«With the current unmet need of alternative solutions to treat infectious diseases, and the development of the immunotherapy field, we decided that was important to set-



up an international scientific congress gathering together high-profile experts from both industry, clinic, academia and biotech to discuss and contribute specifically to the field of immunotherapies against infectious diseases.

Nicolas Groux, Director of Operations at MabDesign.

'It is important and legitimate of BIOASTER to be, with MabDesign, a driving force for the organisation of a congress like this. First of all, the Institute, with its unique technological expertise, is able to answer the industrials' needs in terms of innovation on that subject. Furthermore, it is highly important to create new places to exchange between academics and industrials, at an international level, to help the establishment of new and ambitious collaborative projects in healthcare', clarifies Nathalie Garçon CEO/CSO BIOASTER

The following themes were discussed:

- Immunotherapies against viral infectious diseases
- Immunotherapies as an alternative treatments to antibiotics
- Immunotherapies to fight emerging, re-emerging & bioterrorism infectious diseases.
- Next generation immunotherapies to fight infectious diseases.
- Round table discussion: Challenges on immunotherapy accessibility in emerging countries.

We were able to rely on the participation of speakers, renowned international experts from the pharmaceutical industry such as MedImmune (USA), Arsanis (Austria), Sanofi (France), Humabs (Switzerland), Ablynx (Belgium) as well as experts from the academic field such as the Karolinska Institute (Sweden), Harvard Medical School (USA), Utrecht University (The Netherlands), Technical University of Munich (Germany), l'Institut Pasteur (France) and many more.

Contact Press:

Ana Antunes, MabDesign

ana-sofia.antunes@mabdesign.fr /+33 (0)4 78 02 39 91

Olivier Charzat, BIOASTER,

olivier.charzat@bioaster.org /+33 (0)4 69 84 25 83



ABOUT :

Created in April 2012 by Institut Pasteur and Lyonbiopole health competitiveness cluster, following the initiative of the French government, BIOASTER Technological Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to fight antimicrobials resistance, improve vaccines safety and efficacy, quickly diagnose infections at patient bedside and take full advantage of human and animal microbiota.

In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups that rely on the support of the French Government through the «Investissements d'Avenir» , infrastructures funded by regional authorities (Lyon Metropolis and the Auvergne-Rhône-Alpes Region), world-class academics and industries : (the Pasteur Institute, CEA, CNRS, Inserm, Danone Nutricia Research, Institut Mérieux and Sanofi Pasteur) and from highly dynamic SMEs and regional cluster.

With more than 130 collaborators, coming equally from industries & academics, of which the large majority are scientists and engineers originating from 18 different citizenships, BIOASTER drive new technologies innovation in its own infrastructures with state of the art equipments.

The aim of BIOASTER is to:

- conceives and develops new and innovative high -value technology in the field of microbiology and infectious diseases;
- promotes agility to overlap with the our partner's expectations, and to answer innovation financial issues;

Key figures:

- 7 interconnected technology units, to serve 4 programs: diagnostics, vaccines, antimicrobials & microbiota.
- Total of 2,450 m² of BSL2 & BSL3 laboratories (Lyon & Paris);
- 130 employees, including 80% of scientific experts and representing 18 nationalities.
- 53 projects including 26 with private partners, 25 with public partners.

Contact BIOASTER

www.bioaster.org

contact@bioaster.org

@BIOASTER





ABOUT:

MabDesign is a French membership organization that aims to structure, federate, mobilize and support the development of the industrial sector in the field of immunotherapy. Its creation in 2014, comes from the joint will of four competitiveness clusters (Atlanpole Biotherapies, Eurobiomed, Lyonbiopole, Medicen) and three industrial companies (LFB, Pierre Fabre and Sanofi). Moreover,

MabDesign is issued from governmental and health industry recommendations. MabDesign provides to its members strategic leverage and development opportunities.

In order to accomplish its mission, MabDesign has implemented several actions. On one hand, MabDesign has created a national smart directory of immunotherapy stakeholders, available online; organizes several local and international scientific events per year with high-profile experts in the field; writes prospective reports on strategic topics for the industry; and builds technological cutting-edge training programs to keep the industry sector updated with the necessary skills to maintain competitiveness. On the other hand, MabDesign supports companies' development & competitiveness through customized marketing analysis, specific business development support and technological and commercial surveys. Finally, to promote the development and production of biomedicines on the territory, MabDesign is involved in various government actions dedicated to bioproduction.

Operational since September 2015, MabDesign already counts with 108 + members companies, both pharmaceutical and biotechnology industries, service providers, training organizations and equipment suppliers at the front line of technology innovation.

More information : www.mabdesign.fr | [@MabDesign_fr](https://twitter.com/MabDesign_fr) | contact@mabdesign.fr